<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697161</url>
  </required_header>
  <id_info>
    <org_study_id>OV101-17-001</org_study_id>
    <nct_id>NCT03697161</nct_id>
  </id_info>
  <brief_title>A Study of OV101 in Individuals With Fragile X Syndrome</brief_title>
  <acronym>ROCKET</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ovid Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ovid Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and efficacy of oral OV101
      (gaboxadol) in subjects with Fragile X syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Actual">February 26, 2020</completion_date>
  <primary_completion_date type="Actual">February 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aberrant Behavior Checklist- Community (ABC-C)</measure>
    <time_frame>Change from baseline to week 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical Global Impressions- Improvement (CGI-I)</measure>
    <time_frame>Week 12</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Fragile X Syndrome (FXS)</condition>
  <arm_group>
    <arm_group_label>OV101 (gaboxadol) Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OV101 (gaboxadol) Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OV101 (gaboxadol) Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three Times Daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OV101 (gaboxadol)</intervention_name>
    <description>OV101 (gaboxadol)</description>
    <arm_group_label>OV101 (gaboxadol) Regimen 1</arm_group_label>
    <arm_group_label>OV101 (gaboxadol) Regimen 2</arm_group_label>
    <arm_group_label>OV101 (gaboxadol) Regimen 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is male and 13 to 22 years old (inclusive) at the time of informed consent.

          -  Has a diagnosis of FXS with a confirmed FMR1 full mutation (â‰¥200 CGG repeats).

        Exclusion Criteria:

          -  Concomitant disease or condition that are clinically significant and would limit study
             participation

          -  Clinically significant lab abnormalities or vital signs at the time of screening

          -  History of uncontrollable seizure disorder or seizure episodes within 6 months of
             screening or change in the anticonvulsant pharmacotherapy in the past 3 months.

          -  Unable or does not have a caregiver able to comply with study requirements.

          -  Enrolled in any clinical trial within the 30 days before screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Rakhit, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ovid Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaboxadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

